Back to Search
Start Over
A liver fibrosis cocktail? Psoriasis, methotrexate and genetic hemochromatosis.
- Source :
-
BMC dermatology [BMC Dermatol] 2005 Nov 29; Vol. 5, pp. 12. Date of Electronic Publication: 2005 Nov 29. - Publication Year :
- 2005
-
Abstract
- Background: Pathologists are often faced with the dilemma of whether to recommend continuation of methotrexate therapy for psoriasis within the context of an existing pro-fibrogenic risk factor, in this instance, patients with genetic hemochromatosis.<br />Case Presentations: We describe our experience with two male psoriatic patients (A and B) on long term methotrexate therapy (cumulative dose A = 1.56 gms and B = 7.88 gms) with hetero- (A) and homozygous (B) genetic hemochromatosis. These patients liver function were monitored with routine biochemical profiling; apart from mild perivenular fibrosis in one patient (B), significant liver fibrosis was not identified in either patient with multiple interval percutaneous liver biopsies; in the latter instance this patient (B) had an additional risk factor of partiality to alcohol.<br />Conclusion: We conclude that methotrexate therapy is relatively safe in patients with genetic hemochromatosis, with no other risk factor, but caution that the risk of fibrosis be monitored, preferably by non-invasive techniques, or by liver biopsy.
- Subjects :
- Dermatologic Agents adverse effects
Fatty Liver chemically induced
Fatty Liver diagnosis
Fibrosis etiology
Humans
Male
Methotrexate adverse effects
Middle Aged
Psoriasis complications
Risk Factors
Dermatologic Agents therapeutic use
Hemochromatosis complications
Liver pathology
Methotrexate therapeutic use
Psoriasis drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1471-5945
- Volume :
- 5
- Database :
- MEDLINE
- Journal :
- BMC dermatology
- Publication Type :
- Academic Journal
- Accession number :
- 16316460
- Full Text :
- https://doi.org/10.1186/1471-5945-5-12